This study aimed to assess the knowledge level of street food vendors on hygiene in the Tamale metropolis in the Northern Region of Ghana. The study employed the health belief model as the theoretical basis. Quantitatively, the study employed a descriptive cross-sectional study design to examine the microbial load of street-cut fruits and assess the knowledge and practice of vendors of cut fruits on personal and food hygiene in the study setting. The population consists of cut and vented pawpaw, watermelon, and street fruit vendors registered with the health directorate in the Tamale Metropolis. A convenient sampling technique was used to select 113 respondents for the study. The Yamane formula was used to determine the sample size to select one hundred and thirteen participants (113) out of one hundred and fifty-eight street fruit vendors in the Tamale Metropolis. The main instrument for data collection was a questionnaire. A questionnaire had close-ended questions which were developed using a 'Yes' and 'No' response, and a four-point Likert-type scale ranging from 1=Strongly Disagree (SD), 2=Disagree (D), 3=Agree (A) and 4= Strongly Agree (SA). The data were analysed using descriptive statistics (frequency, percentages, means and standard deviation). The findings revealed that the overall knowledge level of respondents is low. The findings also indicate that vendors do not control the rate at which their customers touch their vended fruits. It is recommended that Street fruit vendors and handlers be educated on fruit hygiene practices through engagement by the Health Directorate Unit of Tamale Metropolis and the Ministry of Health. To keep consumers safe, the Tamale Metropolitan Assembly must strictly enforce compliance with regulations on operation permits and health clearance certificates. Metropolitan sanitation officers must regularly monitor fruit vendors to ensure compliance with goods.

A persistent problem in the pharmaceutical industry that has existed for centuries is the prevalence of counterfeit drugs, and the World Health Organization (WHO) estimates that millions of people are affected by this issue each year. In particular, 4 out of 10 drugs in poor or underdeveloped countries may be adulterated, which can lead to severe adverse events. To address this problem, many countries have implemented regulatory compliance measures such as pharmaceutical drug serialization, which requires the unique identification of every drug package manufactured. This enables tracking and tracing of individual packages throughout the supply chain and helps to prevent counterfeit drugs from entering the market. In this paper, we conduct a systematic review of the serialization process evaluation and its impact on the pharmaceutical industry. We discuss the benefits of pharmaceutical drug serialization, including its ability to improve drug security and reduce adverse events and investigations. We also examine the challenges associated with implementing serialization processes and the regulatory requirements necessary for compliance. Finally, we explore the various tracking and tracing technologies used in serialization processes and their effectiveness in preventing the distribution of counterfeit drugs. Overall, this paper highlights the importance of pharmaceutical drug serialization in ensuring the safety and efficacy of drugs in the healthcare industry, particularly in poor or underdeveloped countries where the problem of adulterated drugs is especially prevalent.

Proper and effective management of obstructive sleep apnea (OSA) in elderly patients represents an important yet under-researched therapeutic target. Therefore, the main purpose of our research was to employ age stratification to analyse sleep quality and sleep fragmentation, the daily sleepiness, OSA severity and CPAP compliance in elderly. Conforming to the inclusion criteria of minimum 70 years of age at the time of polysomnography and CPAP titration night a total number of 162 elderly patients was included, median age 73,00±4 (MED±IQR). The comparison group consisted of 448 adult subjects under the age of 70 years old, median age 54,00±14,00 (MED±IQR). Sleep fragmentation in elderly was promoted to suboptimal CPAP adherence, as the probability of CPAP use ≥ 4 hours per day was less than 20%. Overall CPAP compliance hours in the elderly group achieved 3,991±3,804 hours/day with bigger variation in between the subjects versus 5,547±3,465 hours/day for the controls, (MED±IQR, p<0,001). Despite naturally occurring sleep fragmentation worsened by OSA, less than 30% of elderly patients would score ≥ 10 points on Epworth sleepiness scale. The study emphasizes acute need for standardized age-specific diagnostic tools to address different perception of daily drowsiness and sleepiness by older people. Further, it underlines the importance of early recognition of possible comorbid OSA and insomnia and suggest paying more attention to “non-obese phenotype” in the subgroup of elderly patients with suspected OSA. Elderly patients might also need development of more flexible CPAP compliance criteria; however, those must be standardized and objective.

The construction industry remains one of the most hazardous sectors globally, with Nigeria experiencing a high incidence of workplace accidents despite the adoption of Occupational Health and Safety Management (OHSM) frameworks. This study evaluated the effectiveness of OHSM practices in improving workplace safety across construction companies in Nigeria’s coastal cities. A cross-sectional design was employed, combining quantitative surveys of construction workers (n = 1,400) with qualitative interviews of 35 managers and supervisors. Quantitative data were analyzed using SPSS version 28, while thematic analysis was applied to qualitative responses. Findings revealed a generally positive perception of OHSM, with 54.4% of workers rating OHS policy effectiveness as “Good” and 52.0% rating health outcomes as “Good.” However, accident frequency remained a concern, with 46.4% reporting accidents occurred “Occasionally” and 31.9% acknowledging them as “Frequent” or “Very Frequent.” Comparative analysis showed indigenous firms were rated higher in policy effectiveness and health outcomes but also reported slightly higher accident frequencies than international firms. Thematic analysis identified five key monitoring and evaluation strategies including routine inspections, regular training, audits, behavioural reinforcement, and access control, Also, five measures of OHSM effectiveness, including compliance observation, incident tracking, KPIs, employee feedback, and benchmarking. OHSM was found to positively influence project outcomes by reducing compensation costs, enhancing reputation, and improving supervision and quality of work. OHSM practices in Nigeria’s construction sector are perceived as effective in policy and health outcomes, yet accident rates remain a critical challenge. The study underscores the importance of continuous training, stricter enforcement, behavioural reinforcement, and systematic performance evaluation.

The pharmaceutical industry is undergoing a profound transformation driven by advancements in Information Technology (IT), with Enterprise Resource Planning (ERP) systems playing a pivotal role in reshaping operations. These systems offer integrated solutions that streamline key business processes, such as production, inventory management, supply chain optimization, regulatory compliance, and data integration, contributing significantly to operational efficiency and organizational agility. This paper explores the evolution and impact of ERP systems within the pharmaceutical sector, highlighting their contributions to overcoming the industry’s inherent challenges, including complex regulatory requirements, the need for accurate and real-time data, and the demand for supply chain resilience. The integration of cloud-based ERP solutions, the incorporation of emerging technologies like Artificial Intelligence (AI), Machine Learning (ML), and the Internet of Things (IoT), and enhanced data analytics capabilities have revolutionized pharmaceutical IT. These advancements not only reduce operational costs, improve forecasting accuracy, and enhance collaboration but also ensure compliance with stringent global regulations, such as Good Manufacturing Practices (GMP) and FDA guidelines. Moreover, ERP systems have been instrumental in managing the pharmaceutical supply chain, ensuring product traceability, and improving inventory control and order fulfillment processes. This manuscript examines how ERP systems enable pharmaceutical companies to maintain high standards of product quality, improve decision-making, and ensure the safety and efficacy of drugs through robust tracking and auditing mechanisms. A case study of a pharmaceutical company that implemented an ERP system demonstrates the tangible benefits, including increased operational efficiency, improved compliance rates, and enhanced customer satisfaction. However, despite the clear advantages, challenges such as customization complexities, data integration issues, and resistance to change remain. As the pharmaceutical industry continues to evolve, ERP systems will remain a cornerstone of digital transformation, facilitating smarter decision-making, better resource management, and enhanced collaboration across global operations. This paper also identifies future trends, including the potential of AI and blockchain technologies in further strengthening ERP systems and transforming the pharmaceutical landscape.

In today’s world of a globalized economy and ubiquitous digital transactions, businesses are hungry for ways to increase transaction efficiency and security. In the real economy, solutions that scale to fit transaction volume or velocity are equally valuable. This is true for clearing and settlement and for the day-to-day needs of buyers and sellers alike. Clever observers of both cash and digital transactions can spot cases where technology that supports transaction security or safety can strengthen consumer-borrower ties, mitigate default risks, and reduce recidivism. In general, a cloud solution for payment processing and merchant services solves two major barriers to optimum business technology: lack of scalability and lack of security [1]. The extension of current practice has its advantages, but new solutions unlock significant opportunities for both consumers and financial institutions [2]. The focus of this work is on the provisioning of cloud-based payment processing and merchant services to financial institutions and established global organizations, although the options available with these services mean they are potentially applicable to a wide range of group entities, including non-trading organizations, pension administrators, and group treasurers. With the increased attention to cybersecurity, a mass of data is available to assist the IT departments of the major payment processors, merchants, and acquirers to get cybersecurity on the radar of C-level executives [3]. The case is put forward for the increased targeting of and reporting to the Board’s Audit, Risk, and Liability Committees of publicly held payment processors and merchants to reduce fraud losses and mitigate the reputation and class action lawsuit risk due to data breaches. The progress of technology in the payment sector requires all stakeholders to have a collective approach in order to mitigate fraud and cybersecurity-related risks in new products and services to enhance consumer confidence and the proportion of retail cashless transactions [4].

The pharmaceutical supply chain has become increasingly complex and vulnerable to various risks, including counterfeit drugs, diversion, and fraud. As these challenges threaten patient safety and the integrity of global healthcare systems, serialization has emerged as a pivotal innovation in pharmaceutical logistics and regulatory compliance. Serialization involves assigning unique identifiers to individual drug packages, enabling precise tracking and authentication at every stage of the supply chain. This process provides unprecedented transparency, enhances product security, and facilitates real-time monitoring of pharmaceutical products as they move from manufacturers to end consumers. Despite its potential to revolutionize pharmaceutical traceability, the integration of serialization technologies faces numerous obstacles. These include high implementation costs, regulatory inconsistencies across regions, and the technological challenges of managing vast amounts of data. Moreover, the complex, multi-tiered nature of the global supply chain introduces additional risks related to data integrity, cybersecurity, and interoperability between systems. As pharmaceutical companies seek to navigate these challenges, innovations in serialization technology—such as blockchain, artificial intelligence (AI), the Internet of Things (IoT), and radio frequency identification (RFID)—are providing promising solutions to enhance efficiency, reduce fraud, and increase visibility. This manuscript explores both the innovative advancements and the key challenges associated with the integration of serialization in the pharmaceutical supply chain. It delves into the evolving regulatory landscape, highlighting the need for global harmonization of serialization standards, and examines the impact of serialization on securing pharmaceutical distribution networks. Additionally, the paper emphasizes the importance of collaboration among manufacturers, technology providers, and regulatory bodies in overcoming implementation barriers and realizing the full potential of serialization. As the pharmaceutical industry moves towards a more interconnected and data-driven future, serialization promises to play a central role in shaping the next generation of drug safety and supply chain management. By addressing the hurdles to adoption and leveraging emerging technologies, the pharmaceutical sector can create a more secure, transparent, and efficient supply chain that better serves public health and fosters greater trust among consumers and healthcare professionals alike.

The synthesis and optimization of Active Pharmaceutical Ingredients (APIs) is fundamental to pharmaceutical drug development, directly influencing drug efficacy, safety, and cost-effectiveness. Over recent years, significant advancements in synthetic methodologies and manufacturing technologies have transformed API production. This manuscript provides an overview of the latest innovations in API synthesis, focusing on key techniques such as green chemistry, continuous flow chemistry, biocatalysis, and automation. Green chemistry principles, including solvent substitution and catalytic reactions, have enhanced sustainability by reducing waste and energy consumption. Continuous flow chemistry offers improved reaction control, scalability, and safety, while biocatalysis provides an eco-friendly alternative for synthesizing complex and chiral APIs. Additionally, the integration of automation and advanced process control using machine learning and real-time monitoring has optimized production efficiency and consistency. The manuscript also discusses the challenges associated with regulatory compliance and quality assurance, highlighting the role of advanced analytical techniques such as HPLC, NMR, and mass spectrometry in ensuring API purity. Looking ahead, personalized medicine and smart manufacturing technologies, including blockchain for traceability, are expected to drive further innovation in API production. This review concludes by emphasizing the need for continued advancements in sustainability, efficiency, and scalability to meet the evolving demands of the pharmaceutical industry, ultimately enabling the development of safer, more effective, and environmentally responsible medicines.

Pharmaceutical supply chains are critical to ensuring the availability of safe and effective medications, yet they face numerous challenges that can jeopardize public health. This article provides a comprehensive analysis of the key issues impacting pharmaceutical supply chains, including regulatory compliance, demand forecasting, supply chain visibility, quality assurance, and geopolitical risks. Regulatory compliance remains a significant concern due to the stringent guidelines imposed by authorities such as the FDA and EMA, which can lead to increased operational costs and time delays. Additionally, traditional demand forecasting methods often fail to accurately predict fluctuations in drug demand, resulting in stockouts or excess inventory. Limited supply chain visibility further complicates these challenges, hindering timely decision-making and operational efficiency. Quality assurance is paramount, as maintaining the integrity of pharmaceutical products throughout the supply chain is crucial to preventing costly recalls and ensuring patient safety. Moreover, the globalization of supply chains introduces vulnerabilities to geopolitical risks, trade disputes, and natural disasters. In response to these issues, this article outlines strategic recommendations for optimizing pharmaceutical supply chains. These include leveraging advanced analytics and IoT technologies to enhance demand forecasting and visibility, strengthening compliance through automated systems and training, fostering collaboration among stakeholders, implementing robust risk management frameworks, and investing in quality management systems. By adopting these strategies, pharmaceutical companies can enhance the efficiency and resilience of their supply chains, ultimately ensuring the continuous availability of essential medications for patients worldwide. This analysis serves as a critical resource for industry professionals seeking to navigate the complexities of pharmaceutical supply chains in an increasingly dynamic global environment.

Active Pharmaceutical Ingredients (APIs) serve as the cornerstone of pharmaceutical development, driving therapeutic efficacy and safety in drug formulations. This article provides a comprehensive overview of the lifecycle of APIs, starting from their discovery and development, through to manufacturing processes and regulatory oversight. The development of APIs begins with intensive research and discovery efforts, where medicinal chemists and pharmacologists identify and optimize potential compounds through computational modelling, high-throughput screening, and structure-activity relationship studies. Promising candidates undergo rigorous preclinical testing to assess pharmacological properties, safety profiles, and potential adverse effects in animal models. Upon successful preclinical outcomes, APIs progress to clinical trials, involving phases of testing in human subjects to evaluate efficacy, dosage regimens, and safety profiles under controlled conditions. Clinical trial data are meticulously analyzed to support regulatory submissions, demonstrating the API's therapeutic benefits and safety for eventual patient use. Manufacturing APIs involves complex chemical synthesis or biotechnological methods, ensuring precise control over reaction conditions, purity, and yield. The scale-up from laboratory synthesis to industrial production demands adherence to Good Manufacturing Practices (GMP), where stringent quality control measures verify consistency, potency, and stability throughout production batches. Regulatory oversight by authorities such as the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) in Europe ensures that APIs meet stringent standards of safety, efficacy, and quality before market approval. Manufacturers must submit comprehensive Chemistry, Manufacturing, and Controls (CMC) data, detailing manufacturing processes, analytical methods, and stability studies to support regulatory filings.

Tanga City is the region with several micro-and small-scale pasta processing companies in the country. Therefore, the purpose of this study was to assess the quality and safety of folded vermicelli produced by the small-scale processors in Tanzania. Samples of 1 kg folded vermicelli were collected from 14 processing companies, by the intentional cluster sampling technique. The samples were analysed for aflatoxin and microbiological (Escherichia coli, Aspergillus flavus, and Aspergillus parasiticus) quality. Moreover, physico-chemical quality was assessed in terms of diameter by using a digital calliper, moisture content by oven-drying method at 110℃± 5℃, breaking strength by the texture analyzer, and colour by colourimeter (Chroma Meter CR-400) of the collected samples were determined. In terms of microbial quality, the results indicated contamination by E. coli (1.25-3.00 Log CFU.g^-1 in 8/14 samples), A. flavus (2.23-2.83 Log CFU.g^-1 in 12/14 samples), and A. parasiticus (1.22-2.75 Log CFU.g^-1 in 2/14 samples) as they are beyond the set limits. The diameter varied between 0.90 mm to 1.73 mm in 9/14 samples and moisture content were 10.61% to 12.65% in 13/14 samples, being within the established parameters. The samples indicated low breaking strength with levels between 6.79x10⁵ N.m^-2 to 3.75x10⁶ N.m^-2 in 11/14 samples. The result of brightness (L*) were between 53.03 to 72.14 and yellowness (b*) between 13.68 to 19.48 indices, indicating that there was no significant difference at the 5% level, respectively, although 2/14 samples had red (a*) colour values (-1.32 – +0.56). However, 4/14 samples were detected with aflatoxin B₁ (0.60-0.70 μg.kg^-1), they are within the recommended level (5 μg.kg^-1). The study underscores the need for concerted efforts to enhance production and hygiene practices to ensure consistent compliance with quality and safety standards.

Pharmaceutical Product serialization aims to assign distinct serial numbers to items within a pharmaceutical supply chain. However, this process faces several security challenges like Theft of valid serial numbers may occur, enabling the labelling of counterfeit products. Therefore, it's essential to ensure the uniqueness of serial numbers can be verified at any point in the product's lifecycle within the supply chain. Intimidatory nodes along the distribution network could corrupt planned changes of custody for products. Ensuring verifiability of compliance with these changes is crucial. Manufacturers and consumers need assurance that perishable goods with expired shelf lives are appropriately discarded. In this paper, we review a product serialization method leveraging blockchain technology to address these security concerns within a multi-party perishable goods supply chain. Blockchains offer potential solutions by providing a secure platform for data sharing in multi-party environments, enhancing security and transparency. Within Blockchain technology, each distribution partner is registered to uphold transparency regarding drug information. The system facilitates real-time transfer of ownership changes, recording them as blocks with date and time stamps. This ensures visibility to all partners in real time, maintaining the authenticity of drugs. This article aims to outline how Blockchain technology benefits the pharmaceutical industry by enhancing traceability and trackability of drugs throughout the entire pharmaceutical supply chain.

Pharmaceutical drug traceability is a regulatory compliance adopted by most nations in the world. A comprehensive analysis was carried out to explain the benefits of adopting enterprise system for pharmaceutical drug traceability. Counterfeit drugs are medicines that are fake and have been produced using incorrect potency, or incorrect ingredients used to manufacture these drugs. Solving the drug counterfeiting problems by identifying the most effective and innovative technologies for protecting people's health is of essence these days for the world. Drug serialization is essential concept for drug traceability in the pharmaceutical supply chain. Blockchain is the latest stringent technology that makes drug distribution more secure in the supply chain. The blockchain-based drug traceability is a distributed shared data platform that shares information that is irreversible, reliable, responsible, and transparent in the PSC. Blockchain uses two powerful module, Hyperledger Fabric and Besu to satisfy important criteria for medication traceability, such as privacy, trust, transparency, security, authorization and authentication, and scalability. Researchers in Health informatics can use blockchain designs as a useful road map to develop and implement end-to-end pharmaceutical drug traceability in the supply chain to prevent drug counterfeiting. Industrial IoT is also a key component for the pharmaceutical industry. IoT systems in pharmaceutical drug traceability can be beneficial as they are based on automation and computational methodologies.

For conducting advanced analytics initiatives to acquire in-depth data into usage habits, regional access, sales, and promotional success, etc., unique identification of packaged pharmaceuticals will be a fantastic enabler. The main objective of this study is to prevent and reduce the production of erroneous and counterfeit drugs using the enterprise system, which has become a serious threat because it damages the reputation of legitimate drug manufacturers by trying to produce and market placebo medications that are identical to the real thing. Due to federal government procedures and priorities that frequently change over time, the majority of implementation takes time. To achieve compliance with numerous federal regulatory authorities, including drug traceability for patient safety, the pharmaceutical industry must implement a systematic procedure in an ERP environment. The goals would be to guarantee medical drug traceability and provide real-time warnings to supply chain stakeholders and regulatory bodies to maximize the benefit of integrating a drug traceability system into an ERP environment. Additionally, manufacturers are compelled to maintain product costs on the higher side due to a heavy burden of unchecked manufacturing cost spikes. As a result, innovative marketing schemes must be introduced in order to increase the reach to consumers by putting into practice successful strategies.

Even patients from developed nations have trouble staying on top of their drug compliance. When it comes to improper medicine use, there is an odd parallel between underdeveloped, emerging nations and the so-called developed world in the West. The key factor influencing whether patients stick to their treatment plan is their understanding and perception of the disease.

The equipment used in the construction industry is usually associated with a high impact on the environment. Although sustainable design has shown to be a main player among the initiatives focused on reducing environmental impact, it has been driven by the workers and processes, leaving the equipment endeavors in more restrictive and later stages. The equipment industry has been a constant target of environmental standards and economic pressure, but the increasing technological development allows it to respond to sustainability and safety expectations while enhancing its performance. However, there are still several limitations that lead this sector to be one of the last to reach upgrading levels in terms of development. A study identified some gaps in the equipment design that require a greater effort to effectively support the workers and companies towards sustainable construction. This chapter is based on a study aiming to understand the consolidated knowledge of technologically sustainable equipment design and to identify the challenges left for its full development. The findings support the development of innovative eco-friendly equipment, taking into consideration sustainable materials and product guidelines, as well as green economy initiatives. It also supports complex system approaches and safety by design specificities to establish a corporate knowledge of sustainable equipment and align it with the new regulations of the construction industry. The chapter introduces the context of construction equipment in terms of new challenges when faced with the need to provide construction work with a greater capacity for safety, from an environmental and energy efficiency perspective, and within the paradigm of sustainability. Then, it presents the concept of sustainable equipment considering its principles, followed by a characterization of the agents involved in its life cycle.

The pharmaceutical industry relies extensively on Active Pharmaceutical Ingredients (APIs) as essential components in the production of drugs. The supply chain supporting these APIs is complex, encompassing multiple stages from raw material sourcing to distribution to pharmaceutical manufacturers worldwide. This manuscript explores the intricate challenges encountered within the pharmaceutical API supply chain, focusing on regulatory compliance, quality control, supply chain disruptions, and global dependencies. Regulatory compliance poses a significant hurdle, with varying standards across regions necessitating meticulous adherence to ensure market access and product safety. Quality control and assurance are paramount to maintaining consistency and purity in APIs, yet they present ongoing challenges such as batch variability and contamination risks. Supply chain disruptions, ranging from natural disasters to geopolitical tensions, highlight vulnerabilities in global sourcing strategies, underscoring the need for resilient supply chain management practices. Global dependencies on a limited number of suppliers or regions expose the industry to supply shortages and pricing pressures, exacerbated by geopolitical events and trade policies. These dependencies necessitate strategic diversification and risk mitigation efforts to ensure continuity in API availability and affordability. By addressing these challenges collaboratively, stakeholders can enhance the resilience and reliability of the pharmaceutical API supply chain, thereby ensuring uninterrupted access to essential medications and improving global healthcare outcomes.

Unfortunately, it is not disaster recovery, high availability, or cloud technologies that are inherently difficult to understand, but rather the action of implementing them for software applications that is difficult. The unique method of implementation for a microservices architecture is explored. Regulatory compliance doesn’t stop just because an effective disaster recovery requirement is tough to satisfy for infrastructure unique to sleek microservices. The high-availability location transparency bliss offered by a cloud solution is appealing to a security engineering department. However, the headache starts when the technology presents a handful of undesirable surprises that leak RESTful microservices to the outside world. These are the challenges that post-SOA cloud-resident robustly scalable applications will need to address and overcome. The goal is to explore several popular methods of accomplishing these tough objectives so that engineers can further research the most practical solution. An innovative implementation that leverages Service Bus relays as an elegant disaster recovery solution while enforcing a strict subnet where RESTful microservices solely live will be discussed. The curiosity lies in the atypical experimentation beyond basic gateways and the facility of using such simplicity while still answering day-to-day software development infrastructure challenges for applications we build. Resilient full-service web proxy service crashes and delivery latency switches by harnessing the microservices pod health will also be discussed [1].

The pharmaceutical industry is fundamental to global healthcare, providing essential medicines that improve health outcomes and quality of life. However, the demand and supply dynamics within this sector are highly complex, shaped by various factors including demographic changes, evolving disease burdens, technological advancements, regulatory challenges, and economic pressures. This manuscript explores the intricate relationship between pharmaceutical medicine demand and supply, focusing on key strategies that can help companies effectively navigate these challenges. The demand for pharmaceutical products is driven by several factors, such as population growth, the aging population, the rise of chronic diseases, and the emergence of new health threats. Additionally, healthcare accessibility, affordability, and policy changes significantly impact the consumption of medicines, while innovations in medical technologies and therapies create new treatment needs. On the supply side, pharmaceutical companies face challenges related to manufacturing capacity, raw material availability, distribution logistics, and compliance with ever-evolving global regulatory frameworks. To address these challenges, the manuscript discusses strategic approaches to managing both demand and supply in the pharmaceutical sector. Key strategies include advanced demand forecasting through data analytics, optimizing supply chains for efficiency and resilience, implementing just-in-time inventory models, and investing in flexible manufacturing systems. Furthermore, global collaboration and partnerships, as well as effective risk management practices, are highlighted as essential to ensuring the availability of medicines, particularly in times of crisis or global health emergencies. This manuscript also delves into the role of policy advocacy and regulatory harmonization in stabilizing the pharmaceutical market, ensuring that medicines are accessible to all populations. In conclusion, the pharmaceutical industry must continually adapt to meet the evolving challenges of demand and supply, embracing innovation and collaboration while maintaining a focus on patient access and global healthcare equity. Through strategic planning and adaptive solutions, the pharmaceutical sector can ensure the continuous availability of critical medicines worldwide, meeting both current and future health needs.

The global pharmaceutical supply chain plays a crucial role in ensuring the timely and safe delivery of medicines to patients worldwide. However, the increasing presence of counterfeit drugs within this supply chain poses a significant and growing risk to public health, patient safety, and the integrity of the pharmaceutical industry. Counterfeit drugs—medications that are fraudulently manufactured, mislabeled, or contain incorrect or harmful ingredients—are a major concern as they can lead to ineffective treatments, adverse health effects, and even death. Despite stringent regulatory frameworks and advanced technological solutions, counterfeit drugs continue to infiltrate legitimate supply chains due to factors such as the complexity of the distribution system, global trade practices, and inadequate enforcement in certain regions. This manuscript explores the primary causes behind the proliferation of counterfeit drugs in pharmaceutical distribution, the associated risks, and the multifaceted approaches required to address this growing threat. It discusses the importance of regulatory measures, including international cooperation and stronger compliance frameworks, as well as the role of emerging technologies like serialization, blockchain, and RFID in ensuring traceability and product authenticity. By focusing on the integration of these technologies, the paper also highlights the potential of innovative solutions to enhance transparency, reduce vulnerabilities, and protect the integrity of pharmaceutical supply chains. Additionally, it emphasizes the importance of public awareness campaigns and collaboration between key stakeholders, including pharmaceutical manufacturers, distributors, regulators, and healthcare providers, in creating a more secure and trustworthy pharmaceutical distribution ecosystem. Through a comprehensive exploration of these strategies, this manuscript aims to provide a roadmap for mitigating the risks posed by counterfeit drugs and ensuring the safety and efficacy of medicines for consumers worldwide.

This essay explores how AI can enhance clinical research and, particularly, its pivotal role in the development of medical devices. A data-driven approach to medical device development that can streamline regulatory compliance and quality assurance is discussed. Methods that generate insights from pre-stage data and utilize it during development are detailed. The effectiveness of this approach in compliance audits, 510(k) submissions, and quality system audits - reducing time, effort, and risks is analyzed. The findings are illustrated with practical examples and takeaway recommendations. When reading a scientific article, how many times have you judged the quality of the research by looking at the methodology section? Artificial intelligence algorithms can be developed with the most robust and innovative technology, but if they are not properly validated, they will be worthless in the eyes of regulatory authorities. Conversely, outdated and simplistic models can still gain regulatory clearance if robustness is effectively demonstrated. For better or worse, ethics, economics, and robustness are often sacrificed in the constant government struggle to keep up with the technological edge of AI development. The slow crawl of lawmakers is constant in every field. Automating small tasks can save time and reduce risks when playing catch-up with a changing regulatory framework so the rest of the AI development can continue uninhibitedly. This dives into using FDA open data to collaborate with a food and drug law company and develop several bottom-up initiatives that supply knowledge needed for regulatory compliance and quality systems development. Methods that input pre-stage data and output actionable insights as models are provided. By sharing these resources and advice as academic researchers, efficiency in streamlining processes is maximized, thereby letting more time and resources be allocated to the actual development [1].

Through a digitally connected ecosystem, the innovative realm of fintech significantly enhances human capabilities across various dimensions. AI-based fintech solutions are increasingly proving to be invaluable by providing effective enforcement of regulations that ensure compliance and protect stakeholders involved. Numerous expert investigations conducted in the arena of high-technology litigation have reinforced both the pressing need and the immense value of enforced compliance in today's fast-paced digital landscape. Open banking APIs have boldly pioneered this critical regulatory enforcement role, allowing broader access and improved services for consumers. Predictive AI certainty, facilitated through sophisticated validation systems, represented a fundamental evolution in their rule-based legal formulations that govern many aspects of financial transactions. These advanced products were deployed within global legislative codes, allowing for standardized practices, and consequently, all market sectors quickly adopted them to ensure they remain competitive and compliant. During the latest of these professionals' encouraging comments, it became clear that awareness of the inception of these groundbreaking innovations must be convened into a steadfast commitment to continue launching natural language processing products that can refine consumer interaction. Since this pivotal point, the increasing dependency of the financial expert community on these incisive factors underscores the paramount importance they now hold for their clients and end users alike, shaping the future of finance in profound ways [1].

This paper shows how Big Data Analytics (BDA) and Artificial Intelligence (AI) automation facilitate regulatory compliance in Finance. Regulatory compliance is essential in helping institutions to mitigate reputational, litigation, and financial risk. Existing literature reveals several preconditions for compliance. However, much of the literature has adopted an internal view of compliance without considering external regulatory frameworks. This research draws on the cognitive model of regulation that looks at regulatory compliance as a social construct. It uses a triangulation research method comprising literature review, interview of trade compliance experts, and questionnaire survey of compliance practitioners to understand how regulation affects compliance and what role ICTs play in implementing compliance. The findings of this study present a regulatory compliance framework comprising four cognitive stages and a conceptual regulatory compliance system that presents how BDA and AI automation are applied to mitigate regulatory complexity and enhance regulatory compliance. The conceptual regulatory compliance system shows how BDA and AI enable institutions to dynamically assess regulatory risk, automatically monitor compliance, and intelligently predict risk violations mitigating regulatory complexity and preventing producing unnecessary documents. It provides theoretical contributions to understanding regulatory evolution and compliance and practical implications for understanding how regulation evolves to be more complicated and elements of a regulatory compliance system mitigate proliferating regulations. Additionally, it provides avenues for future research into the relationship between competing regulatory mandates and how institutions cope with that. Regulations are important for ensuring compliance and governance in finance and to curb systemic risk. Complying with regulations is difficult due to their growing volume, complexity, and fragmentation. Institutions use large-scale Information and Communication Technologies (ICTs), such as Big Data Analytics (BDA) and Artificial Intelligence (AI) automation, to monitor compliance and mitigate regulatory complexity. However, less is known about how firms comply with regulation. Most literature does not thoroughly investigate regulatory elements nor explicitly relate them to compliance.

With unclaimed property assets reaching record levels, businesses have become, in some cases, overwhelmed and hamstrung by stagnant, unoptimized processes. That sentiment is compounded by ever-evolving regulatory changes, resulting in organizations struggling to hit compliance deadlines while delivering an optimal claimant experience. Often, early systems had periods of short-term success but are on the verge of obsolescence, resulting in stressed workflows and cumbersome integrations. Deploying an integrated IT infrastructure, supported by cloud-enabled AI, represents the quickest path to modernizing unclaimed property management. A fully integrated IT infrastructure is crucial to optimize the management of unclaimed property [1]. When lone solutions exist across an organization, companies miss out on automation opportunities generated through the interconnectedness of systems and data. AI presents organizations with the opportunity to traverse these gaps, enabling a vast library of applications to improve the perturbed workflows of unclaimed property teams. Automated data extraction, document comparison, fraudulent claim detection, and workflow completion analysis are just a few popular applications well suited for the unclaimed property space. In addition to the lagging technology currently deployed by many organizations, the unclaimed property landscape itself is evolving. Compliance issuance, asset availability, rates, the ability to collect fraudulently posted claims, and the claimant experience have all become hot-button items that are now front of mind for regulation agencies and businesses alike. Issuing duplication letters in a compliant manner, accommodating claimant inquiries regarding held assets, and managing, processing, and understanding the operational impact of rate changes are vexing problems many organizations now find themselves playing catch-up to address. The opportunity posed by cloud-enabled AI is furthered by economic, regulatory, and report cycle pressures on unclaimed property teams to do more with the same size or fewer resources. It’s now no longer simply a case of hitting the audit date deadline and checking off a box but an emerging priority for businesses at all sides of the market, from Fortune 500 to mid-market firms. In-house shared service teams are comfortable in areas of monitoring and curating business data; however, unclaimed property is an unknown territory with a learning curve, compliance gaps, and operational holes that, if ignored, stand to scale up exponentially. The combined fallout from regulatory changes and the recent pandemic have only made the situation riskier, with increased volatility in balancing time-sensitive tasks against stringent regulatory deadlines and growing claimant outreach.

Migrating enterprise policy systems to .NET Core is a key objective of digital transformation in the Insurance IT ecosystem. This change directly addresses strategic drivers: enabling adoption of cloud-first development, resisting market pressure for more flexible and usable enterprise solutions, and preparing for changing demands from regulation and compliance. Phases of operational benefit aligned with risk mitigation form the basis of the migration roadmap, with a strong focus on engaging all relevant stakeholders. Market pressure for a SEAMLESS user experience across ALL applications is a fundamental driver for Investment in digital transformation. Gaps remain in enterprise Operations, where Legislative and regulatory accountability Demand rigid and complex solutions that Liberty has not yet been able to provide. New risk-based capital requirements, Data-Sovereignty controls, Controls for sensitive Data in the Cloud, and new Audit requirements create a long list of challenges for the ecosystem that can no longer be Deferred. At the same time, Cross-organisational integration is becoming more important and integrating partners from the insurance supply-chain requires a much more flexible approach to development and Deployment. These factors combine to generate a credible case for accelerated digital investment with a focus on Migration to Cloud Platforms, with related Risk mitigation, Quality Improvements, and flexibility benefits that close Industry gaps.

The banking sector has shown a strong interest in scaling out and utilizing the microservices architectural pattern within their payments domain, not only to manage increased transaction volumes, but also for compliance and risk-related control. Financial organizations are adopting containerization technologies like Kubernetes and Docker to align with the microservices paradigm. Containerization provides the foundation for automation and operational excellence of microservice-based applications by enabling continuous deployment and automated build-test-release cycles. However, deploying a Kubernetes cluster and the services it hosts in production is not sufficient to guarantee a secure and compliant operating environment. Kubernetes itself should be secured to protect workloads, and risks associated with the services being deployed must be managed continuously.

The global banking industry is subject to ever-growing regulatory requirements, designed to prevent financial tour de force repeats tearing through the world economy. The changes are incomplete and new rules being enacted each year. Implementing and executing these rules and regulations requires the guiding principles from senior management to reach the product desks in a clear and efficient way. Technical systems must implement these rules. Differences in interpretation, implementation, and warnings must be addressed during normal operations. Most importantly, systems must provide warning alerts to management and the business as early as possible, to allow for proper handling. History has shown that the importance of early warnings has been overlooked repeatedly. Real-time capabilities are essential to meet these business needs. Organizations must therefore be ready to embrace a next-generation architecture that enables real-time alert and warning generation. Systems based on a streaming architecture, combined with systems enabling the real-time flow of events between domains supported by orchestration, provide a solid foundation to meet these requirements.

Data quality and data lineage are critical concerns for organizations mandated to comply with stringent regulatory regimes. This paper analyses the latest developments in the governance of data quality and data lineage within a regulated financial services organisation. It sets out the underlying regulatory context, describes the concepts employed in the business environment, summarizes how data quality is captured and monitored, examines the artefacts that record data lineage, reviews the roles and responsibilities of staff who implement the necessary processes, and maps areas where improvements are possible. The internal organization and processes of regulated data platforms are shaped not only by the capabilities prescribed by their technical architecture but also by the regulatory regimes under which they operate. These mandates, in particular, require rigorous examination of four aspects of data quality — accuracy, completeness, consistency, and timeliness — and detailed documentation of how data arrives in its final form in the repository. Although data monitoring, alerting, assessment, and remediation are well established, provenance capture remains an area ripe for further investment.

Healthcare is increasingly recognized as a data-intensive industry. Multi-hospital networks, among other organizations, face mounting operational and governance challenges because of rigid data-integration pipelines that support all data sources and destinations in the network. These pipelines have become difficult to modify, causing them to lag behind the changing needs of the clinical operation. Scalable data-pipeline architectures better support clinical decision making, optimize hospital operations, ease data quality and compliance concerns, and contribute to improved patient outcomes. Meeting scalability goals requires breaking up monolithic data-integration pipelines into smaller decoupled components and aligning service-level agreements of pipeline components and source systems. Parallelization and adoption of distributed data-warehouse technology mitigate the burden of ingesting data into a multi-hospital network. However, latency requirements still warrant the construction of separate pipelines for data ingress from clinical devices, electronic health records, and external laboratory-information systems. Healthcare associations recommend near real-time data availability for a growing list of clinical and operational applications. Mishandling the real-time ingestion of data from clinical devices, in particular, compromises availability and performance. Scalable architectural patterns for real-time streaming Ingestion from heterogeneous data sources, transport processes, and back-end processing structures are detailed.